115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mitochondrial augmentation of hematopoietic stem and progenitor cells as a new therapeutic approach for myelodysplasia
    Meeting Abstract

    Fujino, T.; Avni, N.; Kutner, N.; Khoury, H.; Pozner, G.; Sabath, N.; Castro, C.; Fox, N.; Lewis, A. M.; Tittley, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Delayed neurotoxicity after CAR-T in multiple myeloma: Results from a global IMWG registry
    Meeting Abstract

    Kumar, A. D.; Atallah-Yunes, S. A.; Rajeeve, S.; Abdelhak, A.; Hashmi, H.; Corraes, A.; Htut, M.; Rodriguez-Otero, P.; Parrondo, R. D.; Chhabra, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received ≥1 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): Results from the phase I/II CAMMA 2 study
    Meeting Abstract

    Delforge, M.; Richter, J.; Cohen, Y. C.; Corradini, P.; Sborov, D. W.; Lesokhin, A. M.; Berdeja, J. G.; Gatt, M. E.; Paris, L.; Dachs, L. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Radiation therapy in a new era of multiple myeloma management: Trends of engagement and radiologic, biochemical, and cytogenetic correlates of outcomes and response
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Usmani, S. Z.; Mailankody, S.; Imber, B. S.; Yahalom, J.
    Blood (2024)

    Fulltext@MSK | Save
  • MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Prince, H. M.; Bahlis, N. J.; Rodríguez-Otero, P.; Karlin, L.; Akard, L.; Varshavsky-Yanovsky, A.; Chu, M. P.; Nagai, Y.; Vesole, D. H.; Hickman, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study
    Meeting Abstract

    Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Expanded genome-wide association study (GWAS) identifies nine novel germline risk loci for waldenström macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL)
    Meeting Abstract

    Park, H.; McMaster, M. L.; Hunter, Z. R.; Clay-Gilmour, A. I.; Sucheston-Campbell, L. E.; Breeze, C.; Arias, J.; Davídsson, Ó. B.; Smith-Byrne, K.; Güler, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Topic modeling of genotyping of transcriptomes reveals collaboration between BTK(C481S)-mutant and wild type cells in BTKi-resistant chronic lymphocytic leukemia
    Meeting Abstract

    Massoni-Badosa, R.; Schiffman, J. S.; Pradhan, B.; Murray, R. M.; Lipsky, A. H.; Van Egeren, D.; Luan, D.; Chen, S.; Chaligne, R.; Beattie, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genome-wide meta-analysis identifies multiple germline genetic variants associated with increased risk of follicular lymphoma
    Meeting Abstract

    Joseph, V.; Clay-Gilmour, A. I.; Park, H.; Breeze, C.; Sucheston-Campbell, L. E.; Arias, J.; Waller, R. G.; Güler, M.; Nieters, A.; Smedby, K. E.; more...
    Blood (2024)

    Fulltext@MSK | Save